Amino acid residues 721-729 are required for full factor VIII activity
- PMID: 8575434
- DOI: 10.1111/j.1432-1033.1995.773_a.x
Amino acid residues 721-729 are required for full factor VIII activity
Abstract
Recombinant two-chain factor VIII, from which the B domain had been deleted, was expressed in Chinese hamster ovary cells. In addition to the major product, three minor factor VIII forms were isolated. The A2 domains generated by thrombin cleavage showed different electrophoretic mobilities. Peptide mapping of the A2 domains showed that two of the factor VIII forms had the expected C-terminus of the heavy chain at Arg740 [FVIII-(1-740)] and that the other factor VIII forms had C-termini at Tyr729 [FVIII-(1-729)] or Glu720 [FVIII-(1-720)]. The major FVIII-(1-740) form, FVIII-(1-729), and FVIII-(1-720) contained sulfated tyrosine residues at Tyr718, Tyr719 and Tyr723. The minor FVIII-(1-740) form was shown to lack sulfation at these positions. The specific clotting activity was approximately 1 x 10(4) U/mg for FVIII-(1-740) (both forms) and FVIII-(1-729), but twofold lower for FVIII-(1-720). A time study of thrombin activation showed that FVIII-(1-720) was activated slower than FVIII-(1-740), FVIII-(1-729) and plasma-derived factor VIII. Partially sulfated FVIII-(1-740) was activated at the same rate as the fully sulfated FVIII-(1-740). The equilibrium dissociation constant for binding of factor VIII to inactivated immobilized thrombin was the same for all factor VIII forms, showing that the slower activation of FVIII-(1-720) was not due to a lower affinity for the anion-binding exosite in thrombin.
Similar articles
-
Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII.Biochemistry. 1991 Feb 12;30(6):1533-7. doi: 10.1021/bi00220a013. Biochemistry. 1991. PMID: 1899619
-
Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII.Biochemistry. 1992 Apr 7;31(13):3315-25. doi: 10.1021/bi00128a003. Biochemistry. 1992. PMID: 1554716
-
Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.Thromb Res. 2015 Aug;136(2):388-95. doi: 10.1016/j.thromres.2015.05.005. Epub 2015 May 16. Thromb Res. 2015. PMID: 26037285
-
Structure and function of the factor VIII gene and protein.Semin Thromb Hemost. 2003 Feb;29(1):11-22. doi: 10.1055/s-2003-37935. Semin Thromb Hemost. 2003. PMID: 12640560 Review.
-
Structural and functional characterization of B-domain deleted recombinant factor VIII.Semin Hematol. 2001 Apr;38(2 Suppl 4):4-12. doi: 10.1016/s0037-1963(01)90103-9. Semin Hematol. 2001. PMID: 11449330 Review.
Cited by
-
Blood Clotting Factor VIII: From Evolution to Therapy.Acta Naturae. 2013 Apr;5(2):19-39. Acta Naturae. 2013. PMID: 23819034 Free PMC article.
-
Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.Eur J Haematol. 2014 Nov;93(5):369-76. doi: 10.1111/ejh.12366. Epub 2014 May 28. Eur J Haematol. 2014. PMID: 24797664 Free PMC article. Review.
-
Proteolytic cleavage of recombinant two-chain factor VIII during cell culture production is mediated by protease(s) from lysed cells. The use of pulse labelling directly in production medium.Cytotechnology. 1997 Sep;24(3):227-34. doi: 10.1023/A:1007988713571. Cytotechnology. 1997. PMID: 22358766 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources